A third US patent for Cancer Genetics’ proprietary genomic FHACT cancer test - Prometheus IP

Cancer Genetics Inc., a budding leader in DNA-based cancer diagnostics, proclaimed receiving a third US patent covering FHACT (US patent number 9,157,129), its proprietary FISH (fluorescent in situ hybridization) based HPV associated cancer test and the granted patent is part of a sequence of patents received for FHACT that provide protections for CGI’s proprietary capabilities for the detection of HPV-associated cancers, which include cervical, anal, head and neck, penile, and vulvar cancers.